Biology:N-terminal prohormone of brain natriuretic peptide

From HandWiki
Revision as of 13:56, 11 February 2024 by Wikisleeper (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Precursor of a hormone
natriuretic peptide B
Identifiers
SymbolNPPB
NCBI gene4879
HGNC7940
OMIM600295
RefSeqNM_002521
UniProtP16860
Other data
LocusChr. 1 p36.2

The N-terminal prohormone of brain natriuretic peptide (NT-proBNP or BNPT) is a prohormone with a 76 amino acid N-terminal inactive protein that is cleaved from the molecule to release brain natriuretic peptide 32 (BNP, also known as B-type natriuretic peptide).

Both BNP and NT-proBNP levels in the blood are used for screening, diagnosis of acute congestive heart failure (CHF) and may be useful to establish prognosis in heart failure, as both markers are typically higher in patients with worse outcome.[1] The plasma concentrations of both BNP and NT-proBNP are also typically increased in patients with asymptomatic or symptomatic left ventricular dysfunction and is associated with coronary artery disease, myocardial ischemia, and severity of aortic valve stenosis.[2][3][4][5][6][7]

Blood levels

Upper limit (95th percentile) of blood ranges
for NT-proBNP in healthy people[8]
Sex Age Limit
in pg/mL
Male 19-44 yrs 93
45-54 yrs 138
55-64 yrs 177
65-74 yrs 229
> 75 yrs 852
Females 19-44 yrs 178
45-54 yrs 192
55-64 yrs 226
65-74 yrs 353
> 75 yrs 624
Interpretation Age Range
Congestive heart failure likely <75 years > 125 pg/mL[9]
>75 years >450pg/mL[9]

There is no level of BNP that perfectly separates patients with and without heart failure.[10]

In screening for congenital heart disease in pediatric patients, an NT-proBNP cut-off value of 91 pg/mL could differentiate an acyanotic heart disease (ACNHD) patient from a healthy patient with a sensitivity of 84% and specificity of 42%.[11] On the other hand, an NT-proBNP cut-off value of 318 pg/mL is more appropriate in differing patients with congenital nonspherocytic hemolytic disease (CNHD) from healthy patients, with 94% sensitivity and 97% specificity.[11] An NT-proBNP value of 408 pg/mL has been estimated to be 83% sensitive and 57% specific in differentiating patients with ACNHD from patients with CNHD.[11] In patients with non-severe asymptomatic aortic valve stenosis, increased age- and sex adjusted NT-proBNP levels alone and combined with a 50% or greater increase from baseline had been found associated with increased event rates of aortic valve stenosis related events (cardiovascular death, hospitalization with heart failure due to progression of aortic valve stenosis, or aortic valve replacement surgery).[12]

Test usage in a clinical setting

Canada

While discussed in Canadian medical journals in the mid to late 2000s,[13] the test is not widely used. It was only approved for use in Alberta in February 2012.[14]

Test usage in the life insurance industry

The test has been widely used in the life insurance industry to screen applicants as part of the routine requirements when applying for a life insurance policy. It is also inexpensive and can be measured from blood samples routinely drawn as part of the application process. The test can be used to evaluate for a number of health conditions.[7][15][16]

See also

References

  1. ↑ "B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure". Congestive Heart Failure 10 (1 Suppl 1): 3–27. 2004. doi:10.1111/j.1527-5299.2004.03310.x. PMID 14872150. 
  2. ↑ "A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction". American Heart Journal 148 (3): 518–523. September 2004. doi:10.1016/j.ahj.2004.03.014. PMID 15389242. 
  3. ↑ "Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy". Journal of the American College of Cardiology 39 (10): 1657–1663. May 2002. doi:10.1016/s0735-1097(02)01813-2. PMID 12020494. 
  4. ↑ "Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina". Heart 84 (4): 421–424. October 2000. doi:10.1136/heart.84.4.421. PMID 10995414. 
  5. ↑ "Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome". Circulation Journal 70 (11): 1379–1384. November 2006. doi:10.1253/circj.70.1379. PMID 17062957. 
  6. ↑ "NT-ProBNP independently predicts long-term mortality in patients admitted for coronary angiography". Angiology 65 (1): 31–36. January 2014. doi:10.1177/0003319712462758. PMID 23070682. 
  7. ↑ 7.0 7.1 "Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial". JAMA Cardiology 7 (4): 435–444. April 2022. doi:10.1001/jamacardio.2021.5916. PMID 35171199. 
  8. ↑ "N-terminal-pro-BNP". LABORATORY SERVICES HANDBOOK. The University of Iowa (UIHC), Department of Pathology. 28 May 2020. https://www.healthcare.uiowa.edu/path_handbook/handbook/test2621.html.  Showing 95th percentiles. Epic Lab Code: LAB649.
  9. ↑ 9.0 9.1 Lee MA (2009). Basic Skills in Interpreting Laboratory Data. Amer Soc of Health System. p. 220. ISBN 978-1-58528-180-0. https://books.google.com/books?id=AUSIRcV_as0C&pg=PA220. 
  10. ↑ "Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure". The New England Journal of Medicine 347 (3): 161–167. July 2002. doi:10.1056/NEJMoa020233. PMID 12124404. 
  11. ↑ 11.0 11.1 11.2 "Usefulness of N-Terminal-Pro-B-Type Natriuretic Peptide as a Screening Tool for Identifying Pediatric Patients With Congenital Heart Disease". Laboratory Medicine 42 (2): 75–80. 2011. doi:10.1309/LMW0U87COTHXGELF. 
  12. ↑ "Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial". JAMA Cardiology 7 (4): 435–444. April 2022. doi:10.1001/jamacardio.2021.5916. PMID 35171199. 
  13. ↑ "Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea". CJEM 8 (4): 251–258. July 2006. doi:10.1017/s1481803500013798. PMID 17324304. 
  14. ↑ "B-type Natriuretic Peptide (BNP) & NT-proBNP Test Implementation". Alberta Health Services. http://www.albertahealthservices.ca/6388.asp. 
  15. ↑ "NT-proBNP The Finest Cardiovascular Screening and Reflexive Test In the History of Life Underwriting". Insureintell. 2010. http://www.insureintell.com/sites/insureintell.com/files/NT-proBNP%20II%20-%20final.pdf. Retrieved 11 July 2016. 
  16. ↑ "NT-proBNP as a predictor of all-cause mortality in a population of insurance applicants". Journal of Insurance Medicine 44 (1): 7–16. 2014. PMID 25004594. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:N-terminal_prohormone_of_brain_natriuretic_peptide&oldid=3560936"